Antithrombotische Therapie bei Patienten mit Koronarstent und Vorhofflimmern

Martin Moser; Christoph Bode

doi:10.1055/a-1100-3629

Kardiologie up2date, Table of Contents

Kardiologie up2date 2021; 17(01): 55-65
DOI: 10.1055/a-1100-3629

Thrombozyten und Gerinnungssystem

Antithrombotische Therapie bei Patienten mit Koronarstent und Vorhofflimmern

Martin Moser

,

Christoph Bode

Abstract

All articles of this category

Die Auswahl eines geeigneten antithrombotischen Regimes für Patienten mit Vorhofflimmern, die sich einer perkutanen Koronarintervention unterziehen müssen, ist in dieser kombinierten Indikation schwierig und mit potenziellen Problemen in Hinblick auf das thrombembolische und Blutungsrisiko behaftet. Dieser Beitrag gibt einen Überblick über die aktuellen Therapieempfehlungen für diese kritische Patientengruppe.

Schlüsselwörter

kombinierte antithrombotische Therapie - NOAK - Blutungsrisiko - Stentthrombose

Full Text

References

Literatur
1 Schomig A, Neumann FJ, Kastrati A. et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996; 334: 1084-1089 doi:10.1056/NEJM199604253341702
2 Neumann FJ, Sousa-Uva M, Ahlsson A. et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J 2019; 40: 87-165 doi:10.1093/eurheartj/ehy394
3 Valgimigli M, Patialiakas A, Thury A. et al. Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates. J Am Coll Cardiol 2015; 65: 805-815 doi:10.1016/j.jacc.2014.11.053
4 Valgimigli M, Bueno H, Byrne RA. et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2018; 39: 213-260 doi:10.1093/eurheartj/ehx419
5 European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery. Camm AJ, Kirchhof P, Lip GY. et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31: 2369-2429 doi:10.1093/eurheartj/ehq278
6 Kirchhof P, Benussi S, Kotecha D. et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016; 37: 2893-2962 doi:10.1093/eurheartj/ehw210
7 Ruff CT, Giugliano RP, Braunwald E. et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014; 383: 955-962 doi:10.1016/S0140-6736(13)62343-0
8 Lip GY, Laroche C, Dan GA. et al. A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry. Europace 2014; 16: 308-319 doi:10.1093/europace/eut373
9 Bang CN, Gislason GH, Greve AM. et al. New-onset atrial fibrillation is associated with cardiovascular events leading to death in a first time myocardial infarction population of 89,703 patients with long-term follow-up: a nationwide study. J Am Heart Assoc 2014; 3: e000382 doi:10.1161/JAHA.113.000382
10 ACTIVE Writing Group of the ACTIVE Investigators. Connolly S, Pogue J, Hart R. et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006; 367: 1903-1912 doi:10.1016/S0140-6736(06)68845-4
11 Leon MB, Baim DS, Popma JJ. et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med 1998; 339: 1665-1671 doi:10.1056/NEJM199812033392303
12 van Rein N, Heide-Jorgensen U, Lijfering WM. et al. Major Bleeding Rates in Atrial Fibrillation Patients on Single, Dual, or Triple Antithrombotic Therapy. Circulation 2019; 139: 775-786 doi:10.1161/CIRCULATIONAHA.118.036248
13 Dewilde WJ, Oirbans T, Verheugt FW. et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet 2013; 381: 1107-1115 doi:10.1016/S0140-6736(12)62177-1
14 Gibson CM, Mehran R, Bode C. et al. Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. N Engl J Med 2016; 375: 2423-2434 doi:10.1056/NEJMoa161159
15 Cannon CP, Bhatt DL, Oldgren J. et al. Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation. N Engl J Med 2017; 377: 1513-1524 doi:10.1056/NEJMoa1708454
16 Lopes RD, Heizer G, Aronson R. et al. Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation. N Engl J Med 2019; 380: 1509-1524 doi:10.1056/NEJMoa1817083
17 Vranckx P, Valgimigli M, Eckardt L. et al. Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial. Lancet 2019; 394: 1335-1343 doi:10.1016/S0140-6736(19)31872-0
18 Lopes RD, Hong H, Harskamp RE. et al. Safety and Efficacy of Antithrombotic Strategies in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Network Meta-analysis of Randomized Controlled Trials. JAMA Cardiol 2019; 4: 747-755 doi:10.1001/jamacardio.2019.1880
19 Galli M, Andreotti F, Porto I. et al. Intracranial haemorrhages vs. stent thromboses with direct oral anticoagulant plus single antiplatelet agent or triple antithrombotic therapy: a meta-analysis of randomized trials in atrial fibrillation and percutaneous coronary intervention/acute coronary syndrome patients. Europace 2020; 22: 538-546 doi:10.1093/europace/euz345
20 Gargiulo G, Goette A, Tijssen J. et al. Safety and efficacy outcomes of double vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials. Eur Heart J 2019; 40: 3757-3767 doi:10.1093/eurheartj/ehz732
21 Lopes RD, Leonardi S, Wojdyla DM. et al. Stent Thrombosis in Patients With Atrial Fibrillation Undergoing Coronary Stenting in the AUGUSTUS Trial. Circulation 2020; 141: 781-783 doi:10.1161/CIRCULATIONAHA.119.044584
22 Angiolillo DJ, Goodman SG, Bhatt DL. et al. Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention: A North American Perspective-2018 Update. Circulation 2018; 138: 527-536 doi:10.1161/CIRCULATIONAHA.118.034722
23 Hindricks G, Potpara T, Dagres N. et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur Heart J 2020;
24 Collet JP, Thiele H, Barbato E. et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2020;